Expression of an anti-botulinum toxin A neutralizing single-chain Fv recombinant antibody in transgenic tobacco

被引:29
作者
Almquist, KC
McLean, MD
Niu, YQ
Byrne, G
Olea-Popelka, FC
Murrant, C
Barclay, J
Hall, JC [1 ]
机构
[1] Univ Guelph, Dept Environm Biol, Guelph, ON N1G 2W1, Canada
[2] Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
toxin; clearance; tobacco; scFv;
D O I
10.1016/j.vaccine.2005.11.014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Botulinum neurotoxins (BoNTs) are the most poisonous substances known and are thus classified as high-risk threats for use as bioterror agents. To examine the potential of transgenic plants as bioreactors for the production of BoNT antidotes, we transformed tobacco with an optimized, synthetic gene encoding a botulinum neurotoxin A (BoNT/A) neutralizing single-chain Fv (scFv) recombinant antibody fragment. In vitro mouse muscle twitch assays demonstrated the functional utility of this scFv extracted from tobacco for neutralizing the paralytic effects of BoNT/A at neuromuscular junctions. Based on the efficiency of the scFv capture process and the dose required to antidote a human being. 1-2 ha of this tobacco could yield up to 4 kg of scFv, which would be enough to contribute to the manufacture of 1,000,000 therapeutic doses of a monoclonal antibody (mAb) cocktail capable of neutralizing the effects of BoNT poisoning. Transgenic plants could provide an inexpensive production platform for expression of multiple mAbs toward the creation of polyclonal therapies (i.e. pooled mAbs) as the next improvement in recombinant antibody therapy. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2079 / 2086
页数:8
相关论文
共 50 条
[1]   Immunomodulation confers herbicide resistance in plants [J].
Almquist, KC ;
Niu, YQ ;
Mclean, MD ;
Mena, FL ;
Yau, KYF ;
Brown, K ;
Brandle, JE ;
Hall, JC .
PLANT BIOTECHNOLOGY JOURNAL, 2004, 2 (03) :189-197
[2]   Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries [J].
Amersdorfer, P ;
Wong, C ;
Chen, S ;
Smith, T ;
Deshpande, S ;
Sheridan, R ;
Finnern, R ;
Marks, JD .
INFECTION AND IMMUNITY, 1997, 65 (09) :3743-3752
[3]   Botulinum toxin as a biological weapon - Medical and public health management [J].
Arnon, SS ;
Schechter, R ;
Inglesby, TV ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Fine, AD ;
Hauer, J ;
Layton, M ;
Lillibridge, S ;
Osterholm, MT ;
O'Toole, T ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Swerdlow, DL ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (08) :1059-1070
[4]   BINARY AGROBACTERIUM VECTORS FOR PLANT TRANSFORMATION [J].
BEVAN, M .
NUCLEIC ACIDS RESEARCH, 1984, 12 (22) :8711-8721
[5]   Pathogen-specific recombinant human polyclonal antibodies: biodefence applications [J].
Bregenholt, S ;
Haurum, J .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (03) :387-396
[6]   Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies [J].
Brossier, F ;
Lévy, M ;
Landier, A ;
Lafaye, P ;
Mock, M .
INFECTION AND IMMUNITY, 2004, 72 (11) :6313-6317
[7]   Starlink corn: A risk analysis [J].
Bucchini, L ;
Goldman, LR .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2002, 110 (01) :5-13
[8]  
Cardoso DF, 2000, SCAND J IMMUNOL, V51, P337
[9]   Passive antibody therapies: Progress and continuing challenges [J].
Casadevall, A .
CLINICAL IMMUNOLOGY, 1999, 93 (01) :5-15
[10]   Passive antibody administration (immediate immunity) as a specific defense against biological weapons [J].
Casadevall, A .
EMERGING INFECTIOUS DISEASES, 2002, 8 (08) :833-841